(C) | 1. | ¤@¦ì¯f¤H¦b¦í°|·í¤Ñ©Ò°µªº¦å²G©Ù¤ù¦p¹Ï©Ò¥Ü¡A½Ð°Ý¯f¤H³Ì¥i¯à¬O¦³¤U¦C¦óºØª¬ªp¡H |
A. | ¥¨¥À¬õ¦å²y¡]megaloblastic¡^³h¦å |
B. | ¦ÛÅé§K¬Ì©Ê·»¦å©Ê³h¦å |
C. | ®ü¬v©Ê³h¦å |
D. | ·L²Ó¦åºÞ¯fÅÜ©Ê¡]microangiopathic¡^·»¦å©Ê³h¦å |
E. | ¿ò¶Ç©Ê²y§Î¬õ¦å²y¯g¡]spherocytosis¡^ |
|
(C) | 2. | ¤@¦ì¯f¤H¦]¦å²G¬Û²§±`¡A°µ¤F°©Åè¬ï¨ëÀˬd¡Aµ²ªGÅã¥Ü°©Å褤ªÞ²ÓM¦û¤F45¢H¡F³o¨ÇªÞ²ÓM¤Æ¾Ç¬V¦âperoxidase¬°³±©Ê¡Anonspecific esterase¬°³±©Ê¡A§K¬Ì²ÓM§ÜìÀˬdµ²ªG¦p¤U¡GCD2(-)¡ACD3(-)¡ACD10(-)¡ACD13(+)¡ACD19(-)¡ACD33(+)¡ACD41(-)¡C½Ð°Ý¦¹¯f¤Hªº¶EÂ_¬°¡G |
A. | Acute lymphoblastic leukemia ¡]ALL¡^¡AT-cell |
B. | ALL¡AB-cell |
C. | Acute myeloid leukemia¡]AML¡^¡Aminimally differentiated¡]¢Û0¡^ |
D. | AML¡Amonocytic¡]M5¡^ |
E. | AML¡Amegakaryoblastic¡]M7¡^ |
|
(A) | 3. | ¤@¦ì°ü¤H©â¦åÀˬd®Éµo²{¦å¤pªO¬°26,000/£gl¡A¦å¬õ¯À¤Î¥Õ¦å²y¥¿±`¡C¦¹°ü¤H°£¤p»L¤W¦³»´·L·ï«C¥~µL¨ä¥L¥X¦å²{¶H¡A½Ð°Ý¤U¦C±Ôz¦óªÌ¬O¿ù»~ªº¡H |
A. | ¦¹°ü¤H¦³¤º¥X¦åªº¦MÀI¡A»Ýn¿éª`¦å¤pªO¿@ÁY²G¡C |
B. | »Ý¸ß°Ý¥ÎÃÄ¥v¡A¦]¬°«Ü¦hÃĪ«¦ppenicillins, cephalosporinsµ¥¥i³y¦¨¦å¤pªO¼Æ¥Ø§C¤U¡C |
C. | ¤j³¡¥÷ÃĪ«¤Þ°_ªº¦å¤pªO¼Æ¥Ø§C¤U¥i¦b°±ÃÄ7¦Ü10¤Ñ«á³vº¥¦^´_¡C |
D. | ¨xµw¤Æ¯f¤H·|¦]¬°µÊŦ¸~¤j¦©¯d¸û¦h¦å¤pªO¦b¸Ì±¡A¦Ó³y¦¨¦å¤¤¦å¤pªO¼Æ¥Ø°§C¡C |
E. | Heparin³y¦¨¦å¤pªO§Cªºì¦]¡A¤j¦h¬O¦]¬°§ÜÃĪ«§ÜÅéªþµÛ¦b¦å¤pªO¤W¦Ó³y¦¨¡C |
|
(D) | 4. | ¤U¦C¦óºØ¯e¯f¡AY¹ï¤@¯ë¤ÆªvÀøµL®Ä®É¡A¥i¥H¨Ï¥ÎthalidomideªvÀø¡A¬ù30¢H¦Ü40¢Hªº¯f±w¨ä¯e¯f¥i¥H±o¨ì§ïµ½¡H |
A. | «æ©Ê«e°©Åè²ÓM¥Õ¦å¯f |
B. | ºC©Ê°©Åè©Ê¥Õ¦å¯f |
C. | À±º©«¬¤j²ÓM²O¤Ú½F |
D. | ¦hµo©Ê°©Åè½F |
E. | °©Åè¼W¥Í¤£¨}¯gÔ¸s |
|
(B) | 5. | ¤@¦ì58·³¯f¤H©â¦åµ²ªG¦p¤U¡GHb 5gm/dL, Hct 15¢H, WBC 1,300/£g¢Ú, ¨ä¤¤absolute neutrophils¬°470/£g¢Ú, platelet 1,500/£gl¡C°©ÅèÀˬdÅã¥Ü¬°¦A¥Í¤£¨}©Ê³h¦å¡A½Ð°Ý¹ï¦¹¯f¤H³Ì¾A¦XªºªvÀø¬°¡G |
A. | ¤ä«ù©ÊÀøªk¤Î²§Åé°©Åè²¾´Ó |
B. | ¤ä«ù©ÊÀøªk¤Îµ¹¤©§ÜT²ÓM²y³J¥Õ¥[¤WÀôÌU¯À¤ÎÃþ©T¾J |
C. | ¤ä«ù©ÊÀøªk¤ÎªA¥Î¨k©Ê¶Pº¸»Xl¥Íª« |
D. | ¤ä«ù©ÊÀøªk¤ÎªA¥ÎÃþ©T¾J |
E. | ¤ä«ù©ÊÀøªk |
|
(B) | 6. | ¤U¦C¦³Ãö²O¤Ú²ÓM´c©Ê¯fªº±Ôz¡A¦óªÌ¬O¿ù»~ªº¡H |
A. | ºC©Ê¢Ð²O¤Ú²ÓM¥Õ¦å¯f¡]CLL¡^ªº²ÓMªí±¦h·|ªí²{CD5§Üì¡A¥i»P¥¿±`¢Ð²O¤Ú²ÓM°Ï§O |
B. | B-CLL Rai¹s´Áªº¯f¤H¡]¥u¦³²O¤Ú²ÓM¹L¦h¡AµL¨ä¥L¦å²y¡B¨x¡BµÊ²§±`¡^¡A³Ì¦n°µ¤Æ¾ÇªvÀø¡Aªv¡ªº¾÷·|«Ü¤j |
C. | Follicular lymphoma±`¦³¬V¦âÅ鲧±`t¡]14¡F18¡^ |
D. | À±º©«¬¤j²ÓM²O¤Ú½FªºªvÀø¥H¦X¨Ö¤Æ¾ÇªvÀø¬°¥D |
E. | GªºMALT²O¤Ú½F¦h»PHelicobacter pylori¡]HP¡^·P¬V¦³Ãö¡A¥i¥H¥ÎÃIJM°£¦¹²Óµß±o¨ì²¬Â¡ |
|
(E) | 7. | ¤U¦C¦³ÃöÃþ¦å¤Í¯f¡]von Willebrand disease¡^±`¨£ªº¹êÅç«Ç²§±`¡A¦óªÌ¬O¿ù»~ªº¡H |
A. | aPTT¡]activated partial thromboplastin time¡^©µªø |
B. | ¥X¦å®É¶¡©µªø |
C. | vWF¡]von Willebrand factor¡^¡GAg¡]antigen¡^¿@«×¤U° |
D. | Factor VIII¬¡©Ê¤U° |
E. | vWF¡GRcoF¡]restocetin cofactor¡^¥¿±` |
|
(A) | 8. | ³y¦¨TRALI¡]transfusion-related acute lung injury¡^ªºì¦]¬O¤U¦Cþ¤@¶µ¡H |
A. | ¿é¤Jªº¦å¼ß¤¤±a¦³°ª¿@«×§Ü¤HÃþ¥Õ¦å²y§Üì¡]HLA¡^¤§§ÜÅé¡A»P¨ü¦åªÌªº¥Õ¦å²y§@¥Î¦Ó³y¦¨ |
B. | ¿é¤Jªº¦å¼ß¤¤±a¦³°ª¿@«×§Ü¬õ¦å²y§Ü줧§ÜÅé¡A»P¨ü¦åªÌªº¬õ¦å²y§@¥Î¦Ó³y¦¨ |
C. | ¨ü¦åªÌÅ餺¦³§ÜHLAªº§ÜÅé¡A»P¿é¤J¤§¦å²G¦¨¤À¤¤ªº¥Õ¦å²y§@¥Î¦Ó²£¥Í |
D. | ¿é¤Jªº¦å²G¦¨¤À¤¤¦³·L¥Íª«¡A³y¦¨¨ü¦åªÌ¤ÏÀ³ |
E. | ¬°¤@ºØ²¾´ÓÅé§Ü±J¥D¤ÏÀ³ |
|
(E) | 9. | ¤U¦C¦óªÌ¬O´c©Ê³h¦å¡]pernicious anemia¡^¯f¤H¥Í¤ÆÀˬd¥i¯à¥X²{ªº²{¶H¡H1. ¤j¦å²y©Ê³h¦å¡]macrocytic anemia¡^2. ¶¡±µÁx¬õ¯À¼W°ª¡]indirect hyperbilirubinemia¡^3. ¨Å»Ä²æ²BúC¡]lactate dehydrogenase, LDH¡^¼W°ª4. ¥Õ¦å²y¼Æ¥Ø´î¤Ö5. ¦å¤pªO¼Æ¥Ø´î¤Ö |
A. | 1 |
B. | 1+3 |
C. | 1+2+3 |
D. | 1+4+5 |
E. | 1+2+3+4+5 |
|
(D) | 10. | ¤U¦C¦óºØª¬ªp·|¤Þ°_thrombocytosis¡H1. ´c©Ê¯f2. ¥Òª¬¸¢¾÷¯à¤®¶i3. µÊŦ¤Á°£4. ·P¬V5. ¥X¦å |
A. | 1+3 |
B. | 3+4 |
C. | 1+2+3 |
D. | 1+3+4+5 |
E. | 1+2+3+4+5 |
|